Page 2:
> On day 6, 34 out of 47 (72%) patients in the ivermectin arm reached the endpoint, compared to 21/ 42 (50%) in the placebo arm (OR 2·62; 95% CI: 1·09-6·31).
Page 21:
> 57 were assigned to Ivermectin group, 7 had SARS-CoV-2 RT-PCR with Ct value >35 in the two first tests, 3 were lost for follow up, 47 were eligible for analysis
> 59 were assigned to Placebo group, 14 had SARS-CoV-2 RT-PCR with Ct value >35 in the two first tests, 3 were lost for follow up, 42 were eligible for analysis
Note that "Ct >35" means that the viral charge was so low that after amplifying the virus 35 times they weren't able to detect it. If we add them to the people with a good outcome, we get:
41 out of 54 (76%) patients in the ivermectin arm reached the "endpoint", compared to 35 out of 56 (61%) in the placebo arm.
And this is probably not statistically significant any more.